The Scottish Medicines Consortium (SMC) has published its medicine recommendations for November 2019 including a new combination breast cancer treatment.
The SMC says:
“Ribociclib (Kisqali), used in combination with another medicine, fulvestrant, was accepted for post-menopausal women living with the most common form of advanced breast cancer following consideration through the SMC’s Patient and Clinician Engagement (PACE) process, which is used for medicines to treat end of life and very rare conditions.”
Four other medicines were accepted at the meeting: lenvatinib for renal cell carcinoma, pentosan polysulfate sodium for bladder pain syndrome, clostridium botulinum neurotoxin type A for chronic sialorrhoea, and imiquimod for actinic keratosis.
The details of these appraisals have been added to MAP’s HTA database. Contact email@example.com to find out more about how MAP’s analysis can help solve your market access challenges.
The SMC press release is available here.